ARCT logo

ARCT Stock Overview

Profile

Full Name:

Arcturus Therapeutics Holdings Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

May 22, 2013

Indexes:

Not included

Website:

http://arcturusrx.com

Description:

Arcturus Therapeutics Holdings, Inc. is a pharmaceutical company specializing in the development of drugs for the treatment of liver and respiratory diseases. The company was founded in 2013 with headquarters in San Diego, California. Arcturus Therapeutics is involved in the discovery and development of RNA-based drugs, including the production of RNA drug substance and drug product in nanoparticle form, as well as the development of vaccines against infectious diseases using self-transcribing and replicating RNA (STARR) technology. The company has several preclinical programs, including the LUNAR-OTC program, which is developing mRNA compounds for the treatment of ornithine transcarbamylase (OTC) deficiency, the LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis patients, as well as LUNAR-CV and LUNAR-MD programs.

Key Details

Price

$14.26

Market Cap

$386.59 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$138.39 M(-12.27% YoY)

Annual EPS

-$3.00(-167.86% YoY)

PE Ratio

-

Annual ROE

-31.16%

Annual Debt To Equity

0.00

Beta

1.54

Events Calendar

Earnings

Next earnings date:

May 8, 2025

Recent quarterly earnings:

Mar 6, 2025

Recent annual earnings:

Mar 6, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Nov 16, 2017

Analyst ratings

Recent major analysts updates

Mar 10, 25 Canaccord Genuity
Buy
Mar 7, 25 Wells Fargo
Overweight
Mar 7, 25 HC Wainwright & Co.
Buy
Mar 7, 25 Cantor Fitzgerald
Overweight
Feb 18, 25 HC Wainwright & Co.
Buy
Feb 14, 25 HC Wainwright & Co.
Buy
Jan 13, 25 HC Wainwright & Co.
Buy
Jan 7, 25 HC Wainwright & Co.
Buy
Dec 17, 24 HC Wainwright & Co.
Buy
Dec 16, 24 Cantor Fitzgerald
Overweight

Screeners with ARCT included

Growing Shares Outstanding
US stocks
Stocks with high beta
Stocks below SMA 200
Most recommended stocks
Best performing stocks last 5 years
Stocks below analysts price target
Healthcare sector
All stocks
NASDAQ Listed Companies

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$14.26
ARCT price is $14.26

Price All-time High

$178.57
ARCT price is currently -92.02% below its historical high of $178.57

Price Analysts Target

$66.50
ARCT price is currently -78.56% lower than the consensus analysts' forecast

Price Today Change

+4.43%
ARCT price is up +4.43% today

Price YTD Change

-16.1%
ARCT price is down -16.1% since January 1st

Price 3-Year Change

-22.53%
ARCT price is down -22.53% over the past 3 years

Market cap

Market Cap

$386.59 M
ARCT market capitalization is $386.59 million

Market Cap 3-Year Change

-20.34%
ARCT market capitalization is down -20.34% over the past 3 years

Market Cap All-time High

$3.06 B
ARCT market capitalization is currently -87.38% below its historical high of $3.06 billion

Market Cap Sector Rank

64.25%
ARCT market capitalization is higher than 64.25% of companies in Healthcare sector

Technical

Beta

1.54
ARCT beta is 1.54

200-day SMA

$20.84
ARCT price is currently -31.58% below its 200-day simple moving average

14-day RSI

44.84
ARCT 14-day relative strength index is 44.84

30-day Relative Volume

1.22
ARCT 30-day relative volume is 1.22

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$138.39 M
ARCT annual revenue is $138.39 million

Annual Revenue Analysts Estimate

$124.72 M
ARCT annual revenue is currently +10.96% higher than the consensus analysts' forecast

Annual Revenue 1-Year Change

-12.27%
ARCT annual revenue is down -12.27% year-on-year

Annual Revenue Sector Rank

59.18%
ARCT annual revenue is higher than 59.18% of companies in Healthcare sector

Profit

Annual Gross Profit

-
ARCT annual gross profit value is unknown

Annual Gross Margin

-
ARCT annual gross profit margin value is unknown

Annual Operating Profit

-$95.67 M
ARCT annual operating income is -$95.67 million

Annual Operating Margin

-69.13%
ARCT annual operating profit margin is -69.13%

Annual Net Income

-$80.94 M
ARCT annual net profit is -$80.94 million

Annual Net Margin

-58.49%
ARCT annual net profit margin is -58.49%

EPS

Annual EPS

-$3.00
ARCT annual earnings per share is -$3.00

Annual EPS Analysts Estimate

-$3.77
ARCT annual earnings per share is currently -20.46% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

-167.86%
ARCT annual earnings per share is down -167.86% year-on-year

Annual EPS Sector Rank

32.15%
ARCT annual earnings per share is higher than 32.15% of companies in Healthcare sector

ROA & ROE

Annual ROA

-20.93%
ARCT annual return on assets is -20.93%

Annual ROE

-31.16%
ARCT annual return on equity is -31.16%

EBIT & EBITDA

Annual EBIT

-$80.94 M
ARCT annual earnings before interest & taxes is -$80.94 million

Annual EBITDA

-$77.40 M
ARCT annual EBITDA is -$77.40 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
ARCT price to earnings ratio value is unknown

PE Ratio Sector Rank

-
ARCT price to earnings ratio is unknown

PB Ratio

PB Ratio

1.60
ARCT price to book ratio is 1.60

PB Ratio Sector Rank

54.33%
ARCT price to book ratio is higher than 54.33% of companies in Healthcare sector

PS Ratio

PS Ratio

2.79
ARCT price to sales ratio is 2.79

PS Ratio Sector Rank

48.5%
ARCT price to sales ratio is higher than 48.5% of companies in Healthcare sector

Enterprise value

Enterprise Value

$178.11 M
ARCT enterprise value is $178.11 million

Enterprise Value Sector Rank

55.48%
ARCT enterprise value is higher than 55.48% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-2.56
ARCT EV/EBITDA is -2.56

EV/EBITDA Sector Rank

31.99%
ARCT EV/EBITDA is higher than 31.99% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

4.67
ARCT annual current ratio is 4.67

Annual Quick Ratio

-
ARCT annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.00
ARCT annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-
ARCT annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
ARCT piotroski f-score value is unknown

Altman Z-Score

0.89
ARCT altman z-score is 0.89

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$344.07 M
ARCT annual total assets is $344.07 million

Annual Non Current Assets

$38.09 M
ARCT annual long term assets is $38.09 million

Annual Current Assets

$305.98 M
ARCT annual total current assets is $305.98 million

Annual Cash & Cash Equivalents

$237.03 M
ARCT annual cash & cash equivalents is $237.03 million

Equity

Annual Book Value

$240.98 M
ARCT annual book value is $240.98 million

Annual Working Capital

$240.49 M
ARCT annual working capital is $240.49 million

Liabilities

Annual Total Liabilities

$103.09 M
ARCT annual total liabilities is $103.09 million

Annual Total Long Term Liabilities

$37.60 M
ARCT annual total long term liabilities is $37.60 million

Annual Current Liabilities

$65.49 M
ARCT annual total current liabilities is $65.49 million

Annual Accounts Payable

$7.19 M
ARCT annual accounts payable is $7.19 million

Debt

Annual Total Debt

$28.55 M
ARCT annual total debt is $28.55 million

Annual Total Debt 1-Year Change

-5.51%
ARCT annual total debt is down -5.51% year-on-year

Annual Long Term Debt

$25.00 M
ARCT annual long term debt is $25.00 million

Annual Short Term Debt

$3.55 M
ARCT annual short term debt is $3.55 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$234.06 M
ARCT annual total expenses is $234.06 million

Annual Operating Expenses

$234.06 M
ARCT annual total operating expenses is $234.06 million

Annual Cost Of Goods Sold

-
ARCT annual cost of goods sold value is unknown

Annual SGA

$52.82 M
ARCT annual SGA is $52.82 million

Annual D&A

$3.54 M
ARCT annual depreciation & amortization is $3.54 million

Annual Interest Expense

$0.00
ARCT annual interest expense is $0.00

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$59.75 M
ARCT annual cash flow from operations is -$59.75 million

Annual CFO 1-Year Change

-230.11%
ARCT annual cash flow from operations is down -230.11% year-on-year

Annual CFI

-$648.00 K
ARCT annual cash flow from investing activities is -$648.00 thousand

Annual CFI 1-Year Change

+77.66%
ARCT annual cash flow from investing activities is up +77.66% year-on-year

Annual CFF

$5.42 M
ARCT annual cash flow from financing activities is $5.42 million

Annual CFF 1-Year Change

+122.49%
ARCT annual cash flow from financing activities is up +122.49% year-on-year

Free CashFlow

Annual FCF

-$60.40 M
ARCT annual free cash flow is -$60.40 million

Annual FCF 1-Year Change

-187.6%
ARCT annual free cash flow is down -187.6% year-on-year

CAPEX

Annual CAPEX

$648.00 K
ARCT annual capital expenditures is $648.00 thousand

Annual CAPEX 1-Year Change

-77.66%
ARCT annual capital expenditures is down -77.66% year-on-year

Institutional Ownership

Similar stocks

ANGO logo
AngioDynamics (ANGO)
AURA logo
Aura Biosciences (AURA)
NYXH logo
Nyxoah SA (NYXH)
MRVI logo
Maravai LifeSciences Holdings (MRVI)
GLUE logo
Monte Rosa Therapeutics (GLUE)
ETON logo
Eton Pharmaceuticals (ETON)
CADL logo
Candel Therapeutics (CADL)
HRTX logo
Heron Therapeutics (HRTX)
ATXS logo
Astria Therapeutics (ATXS)

FAQ

  • What is the ticker symbol for Arcturus Therapeutics Holdings?
  • Does Arcturus Therapeutics Holdings pay dividends?
  • What sector is Arcturus Therapeutics Holdings in?
  • What industry is Arcturus Therapeutics Holdings in?
  • What country is Arcturus Therapeutics Holdings based in?
  • When did Arcturus Therapeutics Holdings go public?
  • Is Arcturus Therapeutics Holdings in the S&P 500?
  • Is Arcturus Therapeutics Holdings in the NASDAQ 100?
  • Is Arcturus Therapeutics Holdings in the Dow Jones?
  • When was Arcturus Therapeutics Holdings's last earnings report?
  • When does Arcturus Therapeutics Holdings report earnings?
  • Should I buy Arcturus Therapeutics Holdings stock now?

What is the ticker symbol for Arcturus Therapeutics Holdings?

The ticker symbol for Arcturus Therapeutics Holdings is NASDAQ:ARCT

Does Arcturus Therapeutics Holdings pay dividends?

No, Arcturus Therapeutics Holdings does not pay dividends

What sector is Arcturus Therapeutics Holdings in?

Arcturus Therapeutics Holdings is in the Healthcare sector

What industry is Arcturus Therapeutics Holdings in?

Arcturus Therapeutics Holdings is in the Biotechnology industry

What country is Arcturus Therapeutics Holdings based in?

Arcturus Therapeutics Holdings is headquartered in United States

When did Arcturus Therapeutics Holdings go public?

Arcturus Therapeutics Holdings's initial public offering (IPO) was on May 22, 2013

Is Arcturus Therapeutics Holdings in the S&P 500?

No, Arcturus Therapeutics Holdings is not included in the S&P 500 index

Is Arcturus Therapeutics Holdings in the NASDAQ 100?

No, Arcturus Therapeutics Holdings is not included in the NASDAQ 100 index

Is Arcturus Therapeutics Holdings in the Dow Jones?

No, Arcturus Therapeutics Holdings is not included in the Dow Jones index

When was Arcturus Therapeutics Holdings's last earnings report?

Arcturus Therapeutics Holdings's most recent earnings report was on Mar 6, 2025

When does Arcturus Therapeutics Holdings report earnings?

The next expected earnings date for Arcturus Therapeutics Holdings is May 8, 2025

Should I buy Arcturus Therapeutics Holdings stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions